Intravenous Dexamethasone Use and Outcomes in Children Hospitalized With Septic Arthritis

Area of Science:

• Pediatric Infectious Diseases
• Clinical Pharmacology
• Health Services Research

Background:

• Septic arthritis treatment typically involves joint drainage and antibiotics.
• Systemic corticosteroids are being explored as an adjunctive therapy to improve patient outcomes.
• Understanding the use and impact of dexamethasone in pediatric septic arthritis is crucial.

Purpose of the Study:

• To describe the variation in intravenous dexamethasone administration among children hospitalized with septic arthritis.
• To evaluate the association between intravenous dexamethasone use and clinical outcomes in this patient population.

Main Methods:

• Retrospective cohort study utilizing the Pediatric Health Information System database.
• Identified children with septic arthritis (ICD-10 code M00.x) and recorded intravenous dexamethasone use (hospital days 0-2).
• Propensity score matching was employed to control for confounding variables between dexamethasone recipients and non-recipients.

Main Results:

• Dexamethasone use varied significantly across hospitals (median 28%).
• In propensity-matched analysis, dexamethasone was linked to shorter hospital length of stay (LOS) and reduced costs.
• Increased opioid use was observed with dexamethasone, but no significant differences in 30-day revisits, postdrainage imaging, or repeat procedures were found.

Conclusions:

• Intravenous dexamethasone in children with septic arthritis is associated with reduced hospital LOS and costs.
• The benefits were observed without an increase in 30-day readmission rates.
• Further investigation via a multicenter randomized trial is warranted to confirm these findings.